Impact of SARS-CoV-2 infection on humoral and cellular immunity in a cohort of vaccinated solid organ transplant recipients
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Ayala Borges, Bernardo
- dc.contributor.author Escobedo, Miguel
- dc.contributor.author Egri, Natalia
- dc.contributor.author Herrera, Sabina
- dc.contributor.author Crespo Barrio, Marta
- dc.contributor.author Mirabet, Sonia
- dc.contributor.author Arias Cabrales, Carlos Enrique
- dc.contributor.author Vilella, Anna
- dc.contributor.author Palou, Eduard
- dc.contributor.author Mosquera, María M.
- dc.contributor.author Pascal, Mariona
- dc.contributor.author Colmenero, Jordi
- dc.contributor.author Farrero, Marta
- dc.contributor.author Bodro, Marta
- dc.date.accessioned 2024-11-11T07:17:03Z
- dc.date.available 2024-11-11T07:17:03Z
- dc.date.issued 2023
- dc.description.abstract The aim of the present study was to determine humoral and T-cell responses after four doses of mRNA-1273 vaccine in solid organ transplant (SOT) recipients, and to study predictors of immunogenicity, including the role of previous SARS-CoV-2 infection in immunity. Secondarily, safety was also assessed. Liver, heart, and kidney transplant recipients eligible for SARS-CoV-2 vaccination from three different institutions in Barcelona, Spain were included. IgM/IgG antibodies and T cell ELISpot against the S protein four weeks after receiving four consecutive booster doses of the vaccine were analyzed. One hundred and forty-three SOT recipients were included (41% liver, 38% heart, and 21% kidney). The median time from transplantation to vaccination was 6.6 years (SD 7.4). In total, 93% of the patients developed SARS-CoV-2 IgM/IgG antibodies and 94% S-ELISpot positivity. In total, 97% of recipients developed either humoral or cellular response (100% of liver recipients, 95% of heart recipients, and 88% of kidney recipients). Hypogammaglobulinemia was associated with the absence of SARS-CoV-2 IgG/IgM antibodies and S-ELISpot reactivity after vaccination, whereas past symptomatic SARS-CoV-2 infection was associated with SARS-CoV-2 IgG/IgM antibodies and S-ELISpot reactivity. Local and systemic side effects were generally mild or moderate, and no recipients experienced the development of de novo DSA or graft dysfunction following vaccination.
- dc.format.mimetype application/pdf
- dc.identifier.citation Ayala-Borges B, Escobedo M, Egri N, Herrera S, Crespo M, Mirabet S, et al. Impact of SARS-CoV-2 infection on humoral and cellular immunity in a cohort of vaccinated solid organ transplant recipients. Vaccines (Basel). 2023 Dec 13;11(12):1845. DOI: 10.3390/vaccines11121845
- dc.identifier.doi http://dx.doi.org/10.3390/vaccines11121845
- dc.identifier.issn 2076-393X
- dc.identifier.uri http://hdl.handle.net/10230/68482
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Vaccines (Basel). 2023 Dec 13;11(12):1845
- dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword COVID-19
- dc.subject.keyword Cellular
- dc.subject.keyword Humoral immunity
- dc.subject.keyword Immunity
- dc.subject.keyword Solid organ transplant recipients
- dc.subject.keyword Vaccination
- dc.title Impact of SARS-CoV-2 infection on humoral and cellular immunity in a cohort of vaccinated solid organ transplant recipients
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion